Samsung Biologics and Eli Lilly to Establish New Gateway Labs in Korea
This collaboration signifies a significant expansion of R&D infrastructure in the APAC region, specifically South Korea.
Establishment of a new Lilly Gateway Labs site in Korea through collaboration.
Samsung Biologics has entered into a collaboration agreement with Eli Lilly and Company to establish a Lilly Gateway Labs (LGL) site in Korea. This partnership aims to leverage Samsung Biologics' expertise to support Lilly's research and development activities, potentially accelerating drug discovery and development processes within the region.
This collaboration signifies a significant expansion of R&D infrastructure in the APAC region, specifically South Korea. By partnering with a leading CDMO like Samsung Biologics, Eli Lilly gains access to advanced capabilities and local expertise, potentially streamlining its drug development pipeline. The presence of LGL in Korea could foster innovation, attract further investment in the local biotech ecosystem, and contribute to the growth of South Korea as a key hub for pharmaceutical research and manufacturing in Asia.
This partnership directly impacts South Korea's position as a growing biotech hub in APAC. It enhances the region's capabilities in drug discovery and development, potentially leading to more localized pharmaceutical innovation and manufacturing. The collaboration strengthens the ties between global pharmaceutical giants and APAC CDMOs.
Where this signal fits in the broader landscape.
https://samsungbiologics.com/media/newsroom/press-releases/samsung-biologics-announces-collaboration-with-lilly-to-establish-new-gateway-labs-site-in-korea
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン